Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma ...
Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm US cohort of phase III CELESTIMO study1Data ...
Advancements in understanding tumor biology, identifying predictive biomarkers, and developing targeted therapies have ...
The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid ...
Key challenges include logistical hurdles, such as the need for specialized training and infrastructure, and financial ...
Blake Horvath threw an 8-yard touchdown pass to Eli Heidenreich with 6:32 remaining — on fourth-and-goal — and No. 22 Navy ...
Corbus Pharmaceuticals Holdings, Inc. ( CRBP) Discusses Phase 1a Single-Ascending and Multiple-Ascending Dose Data December 11, 2025 8:00 AM EST ...
Delhi’s pollution spikes to severe levels (AQI 462), triggering Stage IV GRAP restrictions: vehicle limits, halted ...
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of post-ICI ...
As India navigates a rising chronic disease burden, an ageing population, and growing demand for continuity of care, ...
The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futilityArcus is continuing to expand its development program for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback